In the research, biphenyl (2) was used as starting material to synthesize 4, 4'-bis(2-bromoacetyl)-1, 1'-biphenyl (3) with high yield. Then, 4, 4'-bis[N-tert-butoxycarbonyl-(2S)-pyrrolidine-2-carbonyloxymethylformyl]-1, 1'-biphenyl (5) was synthesized via esterification between 3 and N-tert-butoxycarbonyl-L-proline (4). 4, 4'-Bis[2-[N-tert-butoxycarbonyl-(2S)-pyrrolidine-2-yl]-1H-imidazol-5-yl]-1, 1'-biphenyl (6) was prepared by ammonolysis and cyclization of 5. Compound 6 was deprotected by hydrochloric acid to give 4, 4'-bis[2-[(2S)-pyrrolidine-2-yl]-1H-imidazol-5-yl]-1, 1'-biphenyl tetrahydrochloride (7), which was followed by condensation with N-(methoxycarbonyl)-L-valine (8) to give the N, N'-[(1, 1'-biphenyl)-4, 4'-diylbis [1H-imidazole-5, 2-diyl-(2S)-2, 1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2, 1-ethanediyl]]]biscarbamic acid C, C'-dimethyl ester (9), and 9 went through salt formation with HCl to provide daclatasvir dihydrochloride (1). The total mole yield was 38.5% and purity was 99.75%. The improved process has low cost and mild reaction condition, which is very suitable for industrial production.